| Assay Method Information | |
| | QFRET-based biochemical high throughput dose response assay to identify exosite inhibitors of ADAM10. |
| Description: | Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC) Center Affiliation: Torrey Pines Institute for Molecular Sciences (TPIMS) Assay Provider: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS) Network: Molecular Libraries Probe Production Centers Network (MLPCN) Grant Proposal Number: 1 R03 DA033985-01 Grant Proposal PI: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS) External Assay ID: ADAM10_INH_QFRET_1536_3XIC50 DRUN Name: QFRET-based biochemical high throughput dose response assay to identify exosite inhibitors of ADAM10. Description: Approximately 20-30% of breast cancer patients have tumors that over-express human epidermal growth factor receptor (HER2), which confers an aggressive tumor phenotype and poor prognosis [1-3]. A Disintegrin and Metalloprotease (ADAM) proteases are responsible for amplification of HER2 signaling due to either cleavage of its extracellular domain or release of HER2 |
| Affinity data for this assay | |
|---|---|
| If you find an error in this entry please send us an E-mail | |